J&J, Bayer Fall as FDA Staff Urges Xarelto Not Get Expanded

J&J, Bayer Fall as FDA Staff Urges Xarelto Not Get Expanded

Daniel Acker/Bloomberg

Johnson & Johnson and Bayer AG fell in early trading after U.S. regulators recommended that their blood thinner Xarelto not be approved to prevent stroke in people with the most common abnormal heart rhythm.